OPKO Health, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
OPKO Health, Inc. (OPK) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $30.32 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-03.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2014-03-03
- OPKO Health, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2011-12-31 was $21.83M.
- OPKO Health, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2010-12-31 was -$823.00K.
- OPKO Health, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2013 was $30.32M.
- OPKO Health, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2012 was -$24.77M.
- OPKO Health, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2011 was -$32.15M.
- OPKO Health, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2010 was -$2.75M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|
| 2013-12-31 | $30.32M 10-K · filed 2014-03-03 | ||
| 2012-12-31 | -$24.77M 10-K · filed 2014-03-03 | ||
| 2011-12-31 | $21.83M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-03 | -$32.15M 10-K · filed 2014-03-03 | |
| 2011-09-30 | -$53.98M 10-Q · filed 2011-11-09 | ||
| 2010-12-31 | -$823.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | -$2.75M 10-K · filed 2013-03-18 | |
| 2010-09-30 | -$1.92M 10-Q · filed 2011-11-09 | ||
| 2009-12-31 | -$22.55M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |